BioSpace

Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout

Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.

By BioSpace

1 min read
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights